Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has given written informed consent;~* BMI \< 30 kg/m2;~* Age 18 - 42 (upon starting COH);~* \<3 prior ART cycles (IVF, ICSI and related procedures);~* Baseline (day 2-3 of cycling) FSH \<15 IU/L and E2 \<80 pg/mL;~* Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyps or protruding submucosal fibroids);~* Patients must have at least three retrieved oocytes.~Exclusion Criteria:~* Intramural uterine fibroids that distort the uterine cavity or polyps \>1 cm;~* Stage III or IV endometriosis (no endometriomas);~* Hydrosalpinges;~* History of past poor response to COH resulting in canceling ART;~* Use of thawed/donated oocytes;~* Use of thawed/donated embryos;~* Gestational carrier;~* Patients affected by pathologies associated with any contraindication of being pregnant;~* Hypersensitivity to study medication;~* Uncontrolled adrenal or thyroid dysfunction;~* History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a vaginal progesterone product;~* History of arterial disease;~* Patients with hepatic impairment (liver function tests \> 2x upper limits of normal);~* Patients with dermatologic disease;~* Patients with renal impairment (estimated creatinine clearance \<60 mL/min/1.73 m2);~* Neoplasias (current) or history of neoplasia that may be responsive to progesterone;~* High grade cervical dysplasia;~* History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages, wherein pregnancy developed to a minimum of a gestational sac on TVUS;~* Participation in a concurrent clinical trial or in another trial within the past 2 months;~* Use of concomitant medications that might interfere with the study evaluation;~* Pre-implantation genetic diagnosis/screening

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Progesterone SC (Type: EXPERIMENTAL): None
- Progesterone Tablets (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).